Tag: Colorectal Cancer
Colorectal Cancer: A Biobank of Patient-derived Xenografts
According to GLOBOCAN 2018 data, colorectal cancer (CRC) is the third most deadly and fourth most commonly diagnosed cancer in the world. There were nearly 2 million new cases and about 1 million deaths in 2018. The incidence of...
A Ubiquitination Inhibitor Hakin-1 Potentially Has Efficacy In Colorectal Cancer
Hakai is a 491 amino acid E3 ubiquitin-protein ligase that forms a dimer if zinc is available. This allows Src tyrosine kinase dependant interaction with the transmembrane adhesion protein E-cadherin. This interaction results in ubiquitination and degradation of E-cadherin,...
Celyad’s Off-The-Shelf Cell Therapy CYAD-101 In Colorectal Cancer Dose-Escalation Phase 1 Trial
Celyad, a clinical-stage biopharmaceutical company focused
on the development of CAR-T cell therapies, has announced highlights from the
company’s NKG2D-based CAR-T clinical candidates for the treatment of metastatic
colorectal cancer (mCRC), including its novel, off-the-shelf cell therapy
CYAD-101 and alloSHRINK dose-escalation Phase 1...
Biobanking Science: Biobanking Samples for Colorectal Cancer
Colorectal cancer is the third most common cancer, affecting 1.8 million new patients and causing 862,000 deaths every year (1). Studies show that eating processed or red meat and drinking alcohol may increase the risk for colorectal cancer (2)....
Biobanking Science: Vitamin D Deficiency and Colorectal Cancer
Colorectal cancer is the third most common cancer and causes over 50,000 deaths a year in the US alone (1,2). People with vitamin D deficiency may have an increased risk of developing various cancers, including colorectal cancer, according to...
